PMADS

Id:	acc0004
Group:	1sens
Protein:	P53
Gene Symbol:	TP53
Protein Id:	P04637
Protein Name:	P53_HUMAN
PTM:	acetylation
Site:	unclear
Site Sequence:
Disease Category:	Cancer
Disease:	Hepatocellular Carcinoma
Disease Subtype:
Disease Cellline:	SMMC-7721
Disease Info:
Drug:	pterostilbene
Drug Info:	"Pterostilbene is a naturally occurring stilbenoid compound with potent antioxidant, anti-inflammatory, and potential anticancer properties, also recognized for its role in inhibiting melanogenesis by targeting tyrosinase activity and endothelin antagonism in cosmetic or pharmaceutical applications."
Effect:	activate
Effect Info:	The tumor-killing activity of pterostilbene depends on the enhancement of P53 acetylation in hepatocellular carcinoma.
Note:
Score:	5.0
Pubmed(PMID):	29042910
Sentence Index:	29042910_0
Sentence:	Tumoricidal activities of pterostilbene depend upon destabilizing the MTA1-NuRD complex and enhancing P53 acetylation in hepatocellular carcinoma.

Sequence & Structure:

MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAAPPVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRPILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLKSKKGQSTSRHKKLMFKTEGPDSD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target	Drug name	MOA	Phase	Status	Disease	Source
TP53	EPRENETAPOPT	Cellular tumor antigen p53 stabiliser	3	Completed	myelodysplastic syndrome	ClinicalTrials
TP53	IDASANUTLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	3	Terminated	acute myeloid leukemia	ClinicalTrials
TP53	CENERSEN SODIUM	p53 mRNA antisense inhibitor	2	Terminated	chronic lymphocytic leukemia	ClinicalTrials
TP53	CENERSEN	p53 mRNA antisense inhibitor	2	Completed	acute myeloid leukemia	ClinicalTrials
TP53	CENERSEN	p53 mRNA antisense inhibitor	2	Withdrawn	acute myeloid leukemia	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	essential thrombocythemia	ClinicalTrials
TP53	SIREMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	neoplasm	ClinicalTrials
TP53	IDASANUTLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	neoplasm	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Terminated	small cell lung carcinoma	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Active, not recruiting	polycythemia vera	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	polycythemia vera	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	primary myelofibrosis	ClinicalTrials
TP53	IDASANUTLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Terminated	polycythemia vera	ClinicalTrials
TP53	CONTUSUGENE LADENOVEC	Cellular tumor antigen p53 exogenous gene	2	Unknown status	non-small cell lung carcinoma	ClinicalTrials
TP53	APG115	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	lymphoid leukemia	ClinicalTrials
TP53	CONTUSUGENE LADENOVEC	Cellular tumor antigen p53 exogenous gene	2	Terminated	head and neck malignant neoplasia	ClinicalTrials
TP53	CONTUSUGENE LADENOVEC	Cellular tumor antigen p53 exogenous gene	2	Unknown status	head and neck malignant neoplasia	ClinicalTrials ClinicalTrials
TP53	EPRENETAPOPT	Cellular tumor antigen p53 stabiliser	2	Withdrawn	Mantle cell lymphoma	ClinicalTrials
TP53	TEPRASIRAN	p53 mRNA RNAi inhibitor	2	Completed	Acute kidney injury	ClinicalTrials
TP53	EPRENETAPOPT	Cellular tumor antigen p53 stabiliser	2	Completed	ovarian cancer	ClinicalTrials
TP53	CONTUSUGENE LADENOVEC	Cellular tumor antigen p53 exogenous gene	2	Completed	breast cancer	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	2	Recruiting	endometrial cancer	ClinicalTrials
TP53	CENERSEN	p53 mRNA antisense inhibitor	1	Terminated	myelodysplastic syndrome	ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	1	Active, not recruiting	acute myeloid leukemia	ClinicalTrials ClinicalTrials
TP53	NAVTEMADLIN	Tumour suppressor p53/oncoprotein Mdm2 inhibitor	1	Completed	acute myeloid leukemia	ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets

Small molecule

Antibody

PROTAC

Other modalities

Approved Drug

Advanced Clinical

Phase 1 Clinical

Structure with Ligand

High-Quality Ligand

High-Quality Pocket

Med-Quality Pocket

Druggable Family

Approved Drug

Advanced Clinical

Phase 1 Clinical

UniProt loc high conf

GO CC high conf

UniProt loc med conf

UniProt SigP or TMHMM

GO CC med conf

Human Protein Atlas loc

Approved Drug

Advanced Clinical

Phase 1 Clinical

Literature

UniProt Ubiquitination

Database Ubiquitination

Half-life Data

Small Molecule Binder

Approved Drug

Advanced Clinical

Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

TP53-Lys305
Cancer	Intensity
BRCA	-1.121
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	0.799
non_ccRCC
PDAC
UCEC	0.322

TP53-Lys357
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.707
non_ccRCC
PDAC
UCEC

TP53BP1-Lys1365
Cancer	Intensity
BRCA	-0.326
COAD
HGSC
ccRCC
GBM	1.485
HNSC
LUAD
LUSC	-0.671
non_ccRCC
PDAC
UCEC	-0.488

TP53BP1-Lys1631
Cancer	Intensity
BRCA	-1.355
COAD
HGSC
ccRCC
GBM	0.775
HNSC
LUAD	0.725
LUSC	0.644
non_ccRCC
PDAC
UCEC	-0.79

TP53BP1-Lys1672
Cancer	Intensity
BRCA	-1.476
COAD
HGSC
ccRCC
GBM	0.981
HNSC
LUAD	0.475
LUSC	-0.553
non_ccRCC
PDAC
UCEC	0.573

TP53BP1-Lys1674
Cancer	Intensity
BRCA	0.052
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-1.025
LUSC
non_ccRCC
PDAC
UCEC	0.973

TP53BP1-Lys222
Cancer	Intensity
BRCA	0.901
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-1.128
LUSC	0.781
non_ccRCC
PDAC
UCEC	-0.554

TP53BP1-Lys255
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC	-0.707

TP53BP1-Lys610
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	-0.707
non_ccRCC
PDAC
UCEC

TP53BP1-Lys878
Cancer	Intensity
BRCA	-1.108
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC	0.837
non_ccRCC
PDAC
UCEC	0.271

TP53I3-Lys176
Cancer	Intensity
BRCA	-1.515
COAD
HGSC
ccRCC
GBM	0.409
HNSC
LUAD	-0.378
LUSC	1.124
non_ccRCC
PDAC
UCEC	0.361

TP53I3-Lys177
Cancer	Intensity
BRCA	0.707
COAD
HGSC
ccRCC
GBM	-0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

TP53I3-Lys183
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	0.901
LUSC	0.175
non_ccRCC
PDAC
UCEC	-1.076

TP53I3-Lys193
Cancer	Intensity
BRCA	0.455
COAD
HGSC
ccRCC
GBM	-0.602
HNSC
LUAD	-0.304
LUSC	-1.046
non_ccRCC
PDAC
UCEC	1.498

TP53I3-Lys203
Cancer	Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD	-0.771
LUSC	-0.359
non_ccRCC
PDAC
UCEC	1.13

TP53I3-Lys321
Cancer	Intensity
BRCA	-0.81
COAD
HGSC
ccRCC
GBM	-1.262
HNSC
LUAD	0.289
LUSC	1.09
non_ccRCC
PDAC
UCEC	0.692

PTM-Disease Association:

source: PTMD

Residue	Position	State	Disease	Class	PMID
-	-	A	Colorectal cancer	Ubiquitination	37438558
-	-	A	Cervical cancer	Ubiquitination	30674441
-	-	A	Pancreatic ductal adenocarcinoma	Phosphorylation	36209169
-	-	D	Acute myeloid leukemia	Acetylation	29501566
-	-	D	Acute kidney injury	Ubiquitination	32248569
-	-	D	Ovarian cancer	Ubiquitination	32869837
-	-	D	Ovarian cancer	Ubiquitination	31570706
-	-	D	Breast cancer	Ubiquitination	32571254
-	-	D	Non-small cell lung cancer	Ubiquitination	32248621
-	-	D	Breast cancer/tumor/carcinoma	Acetylation	24920214
-	-	D	Cardiac fibrosis	Acetylation	37408261
-	-	P	Cervical cancer	Ubiquitination	32203172
-	-	P	Lung cancer	Ubiquitination	33328571
-	-	P	Breast cancer	Ubiquitination	34240781
-	-	P	Hepatocellular carcinoma	Ubiquitination	34775479
-	-	P	Esophageal squamous cell carcinoma	Ubiquitination	32066565
-	-	P	Hepatocellular carcinoma	Ubiquitination	31626714
-	-	P	Nasopharyngeal carcinoma	Ubiquitination	35517429
-	-	P	Hepatocellular carcinoma/hepatocarcinoma/hepatoma	Ubiquitination	16581249
-	-	P	Gastric cancer	Ubiquitination	24240108
-	-	P	Melanoma	Phosphorylation	22968364
-	-	P	Pancreatic cancer/carcinoma/adenocarcinoma	Phosphorylation	23845906
-	-	P	Head and neck squamous cell carcinoma	Phosphorylation	23414419
-	-	P	Renal cell carcinoma	Ubiquitination	30874541
-	-	U	Liver fibrosis	Ubiquitination	37495427
-	-	U	Cutaneous T-cell lymphoma	Acetylation	32119867
-	-	U	Hepatocellular carcinoma	Ubiquitination	36252649
-	-	U	Cancer	Ubiquitination	35150809
-	-	U	Cervical cancer	Ubiquitination	35402260
-	-	U	Hepatocellular carcinoma	Ubiquitination	37460074
-	-	U	Hepatocellular carcinoma	Ubiquitination	29928880
-	-	U	Lung cancer	Ubiquitination	31138778
-	-	U	Colorectal cancer	Ubiquitination	33149608
-	-	U	Renal cell carcinoma	Ubiquitination	33622324
-	-	U	Lung adenocarcinoma	Ubiquitination	32553631
-	-	U	Colorectal cancer	Ubiquitination	31239268
-	-	U	Lung cancer	Ubiquitination	31279706
-	-	U	Colorectal cancer	Ubiquitination	31521611
-	-	U	Breast cancer	Neddylation	25867061
-	-	U	Colon cancer	Phosphorylation	35328513

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links:

CTD
DMRdb